Vancouver, Canada — November 24, 2025 — Leads & Copy —
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) announced that its independent Data and Safety Monitoring Board (DSMB) has completed a scheduled interim review of the company’s ongoing FDA-approved Phase I/IIa clinical trial for CMND-100 in the treatment of Alcohol Use Disorder (AUD). The DSMB has unanimously recommended that the clinical trial continue, based on encouraging top-line data from the first cohort, which demonstrated a favorable safety profile.
The multinational, multi-center trial is evaluating the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD. The DSMB includes independent experts including specialists in psychiatry, a biostatistician, and a neuropsychopharmacologist who conducted a thorough review of unblinded safety data from the initial dosing cohort.
Key findings included:
- No serious adverse events (SAEs) reported.
- General good tolerability across all participants.
- Strong treatment observance, with high adherence to the dosing regimen and study protocol.
Dr. Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine, said the DSMB recommendation is a pivotal milestone for Clearmind and reinforces their confidence in CMND-100’s safety and therapeutic potential. He added that the positive interim data positions the company to accelerate enrollment and advance this innovative treatment toward addressing the unmet needs in alcohol use disorder. Dr. Zuloff-Shani also expressed appreciation for the contributions of their clinical sites and study participants.
The DSMB was established in 2023 to oversee the first-in-human aspects of the trial, ensuring ongoing patient safety, data integrity, and scientific validity.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
Investor Relations can be contacted at invest@clearmindmedicine.com or Telephone: (604) 260-1566. US: CMND@crescendo-ir.com. General Inquiries can be directed to Info@Clearmindmedicine.com
Source: Clearmind Medicine Inc.
